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1. INTRODUCTION {#odi13199-sec-0005}
===============

The global consumption of drugs to treat acute and chronic diseases continues to increase (WHO, [2011](#odi13199-bib-0021){ref-type="ref"}). Inevitably, healthcare professionals are frequently confronted with patients using one or more drugs on a daily basis. These drugs can cause adverse effects in the oral region such as xerostomia, hyposalivation, mucositis, and taste disorders.

Due to the large number of different drugs available and their wide range of adverse effects, it is difficult and time‐consuming for healthcare professionals to take all the potential consequences into account during their daily practice. To support oral healthcare professionals in their decision making, the journal of Oral Diseases will publish a series of articles discussing the most frequent adverse effects of drugs in the oral region. The first paper in this series discusses drug‐induced taste disorders (DITD).

Fark, Hummel, Hahner, Nin, and Hummel ([2013](#odi13199-bib-0004){ref-type="ref"}) divided taste disorders into quantitative taste disorders and qualitative taste disorders. Quantitative taste disorders include hypergeusia (an abnormally heightened sense of taste), normogeusia (a normal sense of taste), hypogeusia (an abnormally lowered sense of taste), and ageusia (a lacking sense of taste). Qualitative taste disorders are dysgeusia (a distortion in sense taste) and phantogeusia (a taste perception without a stimulus) (Fark et al., [2013](#odi13199-bib-0004){ref-type="ref"}). Although disturbances in taste seem harmless, they can interfere with a patients' social behavior by avoiding dinners or lead to a change in diet which can, among others, cause weight loss, nutrient deficiencies, or overweight due to excessive use of salt and sugar to compensate bad flavors (Noel, Sugrue, & Dando, [2017](#odi13199-bib-0013){ref-type="ref"}). As such, taste disorders can lead to a significant reduction in the quality of life (Ponticelli et al., [2017](#odi13199-bib-0015){ref-type="ref"}). Therefore, it is important that oral healthcare professionals are aware of the possible causes and treatment modalities of taste disorders. Adverse effects of drugs account for 9%--22% of the taste disorders (Fark et al., [2013](#odi13199-bib-0004){ref-type="ref"}; Hamada, Endo, & Tomita, [2002](#odi13199-bib-0006){ref-type="ref"}). This article aims to support oral healthcare professionals in their decision making whether a taste disorder can be due to use of drugs by providing a comprehensive overview of drugs documented with taste disorders as an adverse effect.

2. MATERIALS AND METHODS {#odi13199-sec-0006}
========================

2.1. Data source {#odi13199-sec-0007}
----------------

The Informatorium Medicamentorum (IM) of the Royal Dutch Pharmacists Association (KNMP) is the leading national drug information database and reference work for pharmacists in the Netherlands. This database is based on scientific drug information, guidelines, and summaries of product characteristics (SmPCs) (KNMP, [2019](#odi13199-bib-0007){ref-type="ref"}). The IM is updated every 2 weeks with the latest available information from scientific publications, warnings of authorities, and SmPCs of the European Medicines Agency and Medicines Evaluation Board in the Netherlands.

The IM was last searched on August 1, 2018, and all data regarding adverse effects available that time were included in this study. Of each drug, the category "side effects" from the IM was searched for taste disorders and synonyms (e.g., dysgeusia).

The following characteristics of drugs causing DITD were registered: generic name of the drug, term of the adverse effect, incidence of the adverse effect, and Anatomic Therapeutical Chemical (ATC) codes of the drug. The ATC classification was developed by the World Health Organization and categorizes all active substances in drugs according to a hierarchy with five levels. It serves as a tool for exchanging data on drug use on a national and international level (WHO, [2003](#odi13199-bib-0020){ref-type="ref"}). It is worth noting that one active substance can be used in different drugs with different treatment goals. Therefore, it is possible that one active substance (e.g., miconazole) has several ATC codes (Figure [1](#odi13199-fig-0001){ref-type="fig"}).

![Hierarchy of ATC levels for miconazole \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](ODI-26-213-g001){#odi13199-fig-0001}

Originally, the terms used to describe one adverse effect (e.g., taste disorders) in the SmPCs varied between drugs and throughout the years. In order to create a standardized structured database, the MedDRA classification was manually applied after the selection of drugs causing DITD. The MedDRA classification is developed by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human and endeavors to standardize all international medical terminology, including terms for adverse effects (Meddra, [2019](#odi13199-bib-0011){ref-type="ref"}). The MedDRA classification is a hierarchical system that distinguishes five levels in the categorization of medical terminology. The most specific level is the "Lowest Level Term (LLT)" and the next level is called the "Preferred Term (PT)." Each LLT is directly linked to only one PT. Each PT is linked to at least one LLT (itself) and sometimes several synonyms of the LLT. In Figure [2](#odi13199-fig-0002){ref-type="fig"}, the PT "Hypogeusia" is presented with its LLTs. After the selection of drugs related to DITD from the IM, the adverse effect terms were first matched in accordance with the support document (Meddra, [2018](#odi13199-bib-0010){ref-type="ref"}), with the most applicable LLT in Dutch. Terms were then translated into English by using the LLT codes and the English version of MedDRA. The English LLT was automatically matched with the English PT level according to the MedDRA hierarchy.

![Hierarchy of "Hypogeusia" in MedDRA \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](ODI-26-213-g002){#odi13199-fig-0002}

Microsoft® Excel (version 16.16.1) was used to create the database with the acquired information on DITD and to perform descriptive statistics.

3. RESULTS {#odi13199-sec-0008}
==========

In total, 1,645 drugs (active substances) were registered in the IM. Each drug can cause multiple adverse effects resulting in approximately 65,000 unique combinations between a drug and an adverse effect in the IM. Of these 65,000 combinations, 2,335 (3.5%) were defined by the authors as relevant for the oral healthcare provider and 343 (0.5%) concerned taste disorders. Of the 1,645 drugs, 314 (19%) could cause DITD. As IM discriminates different administration forms per drug, the number of drugs (314) and number of combinations (343) causing taste disorders differ. For example, "Budesonide," which can be administered rectally, nasally, and by inhalation, is registered three times with dysgeusia as a potential adverse effect with three different incidences. Table [1](#odi13199-tbl-0001){ref-type="table"} presents the different LLTs and PTs used in the IM for taste disorders and the number drugs which can potentially cause them. Taste disturbance as an adverse effect was reported in all level 1 categories of the ATC classification (Table [2](#odi13199-tbl-0002){ref-type="table"}).

###### 

LLTs and PT for taste disorders in IM analysis

  Adverse effect term       No. of drugs
  ------------------------- --------------
  Dysgeusia (PT)            282
  Dysgeusia (LLT)           15
  Taste bitter (LLT)        9
  Taste disturbance (LLT)   245
  Taste garlic (LLT)        1
  Taste metallic (LLT)      12
  Hypogeusia (PT)           61
  Hypogeusia (LLT)          61
  Total                     343

John Wiley & Sons, Ltd

###### 

Number of drugs causing dysgeusia or hypogeusia per ATC level 1 category

  ATC level 1 category                                   Dysgeusia (%)   Hypogeusia (%)   Total
  ------------------------------------------------------ --------------- ---------------- -------
  Alimentary tract and metabolism                        24 (8.5)        2 (3.1)          26
  Antiinfectives for systemic use                        44(15.6)        7 (11.0)         51
  Antineoplastic and immunomodulating agents             53 (18.8)       22 (39.0)        75
  Antiparasitic products, insecticides, and repellents   5 (1.7)         ‐                5
  Blood and blood forming organs                         13 (4.6)        1 (1.4)          14
  Cardiovascular system                                  23 (8.1)        5 (7.8)          28
  Dermatologicals                                        13 (4.6)        2 (3.2)          15
  Genitourinary system and sex hormones                  5 (1.7)         3 (4.7)          8
  Musculoskeletal system                                 12 (4.3)        2 (3.1)          14
  Nervous system                                         39 (13.8)       12 (19.0)        51
  Respiratory system                                     16 (5.7)        ‐                16
  Sensory organs                                         10 (3.5)        1 (1.5)          10
  Systemic hormonal preparations, excl.                  7 (2.5)         2 (3.1)          9
  Various                                                18 (6.3)        2 (3.1)          20
  Total                                                  282             61               343

John Wiley & Sons, Ltd

"Normogeusia," "hypergeusia," "ageusia," and "phantogeusia" were not reported in the IM.

3.1. Dysgeusia {#odi13199-sec-0009}
--------------

Dysgeusia (PT) as an adverse effect was reported 282 times (17.1% of 1,645 drugs) (Table [1](#odi13199-tbl-0001){ref-type="table"}). The drug categories "antineoplastic and immunomodulating agents" (18.8%), "antiinfectives for systemic use" (15.6%), and "nervous system" (13.8%) account for almost half of the drug‐induced dysgeusia (Table [2](#odi13199-tbl-0002){ref-type="table"}). Hypergeusia, ageusia, and phantogeusia were not reported.

Table [3](#odi13199-tbl-0003){ref-type="table"} presents a selection of the drugs that could cause dysgeusia (PT) and comprises only the category "Alimentary tract and metabolism." The frequencies of the adverse effect and whether a drug also causes the adverse effects "parosmia," "anosmia," "dry mouth," or "hyposalivation" are presented as well, since these adverse effects are closely related to taste disorders. In some drugs, dysgeusia is only caused when the drug is administered through a specific route or under certain circumstances. The full table of all the 282 drugs causing dysgeusia is presented online as supplementary data (Table [S1](#odi13199-sup-0001){ref-type="supplementary-material"}).

###### 

Drug‐induced dysgeusia (PT) in level 1 ATC category: alimentary tract and metabolism

  ATC level 1                                                         ATC level 3                                     Generic name                              ATC Code                     LLT MedDRA                   Frequency                          Specific type of administration   Coinciding adverse effects
  ------------------------------------------------------------------- ----------------------------------------------- ----------------------------------------- ---------------------------- ---------------------------- ---------------------------------- --------------------------------- ----------------------------
  ALIMENTARY TRACT AND METABOLISM                                     Antiemetics and antinauseants                   Aprepitant                                A04AD12                      Taste disturbance            Frequency not known                --                                D
  Rolapitant                                                          A04AD14                                         Taste disturbance                         Uncommon (0.1%--1%)          --                           --                                                                   
  Antipropulsives                                                     Loperamide                                      A07DA03                                   Taste disturbance            Frequency not known          --                                 D                                 
  Blood glucose‐lowering drugs Excl. insulins                         Exenatide                                       A10BJ01 A10BJ01                           Taste disturbance            Uncommon (0.1%--1%)          --                                 --                                
  Glimepiride                                                         A10BB12                                         Taste disturbance                         Frequency not known          --                           --                                                                   
  Liraglutide                                                         A10BJ02                                         Taste disturbance                         Common (1%--10%)             --                           D                                                                    
  Metformin                                                           A10BA02                                         Taste disturbance                         Common (1%--10%)             --                           --                                                                   
  Drugs for peptic ulcer and gastroesophageal reflux disease (GORD)   Esomeprazole                                    A02BC05                                   Taste disturbance            Frequency not known          After intravenous administration   D                                 
  Famotidine                                                          A02BA03                                         Taste disturbance                         Uncommon (0.1%--1%)          --                           D                                                                    
  Lansoprazole                                                        A02BC03                                         Taste disturbance                         Frequency not known          --                           D                                                                    
  Rabeprazole                                                         A02BC04                                         Taste disturbance                         Frequency not known          --                           D                                                                    
  Intestinal antiinfectives                                           Fidaxomicin                                     A07AA12                                   Taste disturbance            Uncommon (0.1%--1%)          --                                 D                                 
  Miconazole                                                          A07AC01 D01AC02 G01AF04 S02AA13                 Dysgeusia                                 Common (1%--10%)             After oral administration    D                                                                    
  Miconazole                                                          A07AC01 D01AC02 G01AF04 S02AA13                 Taste disturbance                         Uncommon (0.1%--1%)          After oral administration    D                                                                    
  Intestinal anti‐inflammatory agents                                 Budesonide                                      A07EA06 R01AD05 R03BA02                   Taste disturbance            Uncommon (0.1%--1%)          After rectal administration        D,P                               
  Budesonide                                                          A07EA06 R01AD05 R03BA02                         Taste disturbance                         Common (1%--10%)             After inhalation             D,P                                                                  
  Budesonide                                                          A07EA06 R01AD05 R03BA02                         Taste disturbance                         Frequency not known          After nasal administration   D,P                                                                  
  Cromoglicic acid                                                    A07EB01 R01AC01 R03BC01 S01GX01                 Dysgeusia                                 Uncommon (0.1%--1%)                                       --                                                                   
  Sulfasalazine                                                       A07EC01                                         Taste disturbance                         Common (1%--10%)             --                           A                                                                    
  Other alimentary tract and metabolism products                      Agalsidase alfa                                 A16AB03                                   Taste disturbance            Common (1%--10%)             --                                 A                                 
  Sodium phenylbutyrate                                               A16AX03                                         Taste disturbance                         Common (1%--10%)             --                           --                                                                   
  Stomatological preparations                                         Chlorhexidine                                   A01AB03 B05CA02 D08AC02 D09AA12 S01AX09   Taste disturbance            Rare or very rare (\<0.1%)   --                                 --                                
  Triamcinolone                                                       A01AC01 D07AB09 H02AB08 R01AD11 S01BA05 S02BA   Taste disturbance                         Rare or very rare (\<0.1%)   After nasal administration   --                                                                   
  Hydrogen peroxide                                                   A01AB02                                         Dysgeusia                                 Frequency not known          --                           --                                                                   

Abbreviations: A, anosmia; ATC, Anatomic Therapeutical Chemical; D, dry mouth; LLT, lowest level term; P, parosmia
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In these 282 drugs, the frequency of dysgeusia was "very common" in 7.1%, "common" in 31.2%, "uncommon" in 32.7%, and "rare or very rare" in 9.9% of the drugs. In 19.1% of the drugs, the "frequency was not known," which means that in the IM, the frequency could not be estimated based on the available data.

Dysgeusia coincided in 114/282 drugs (40.4%) with "dry mouth" as an adverse effect, in 5/282 drugs (1.7%) with "anosmia," in 2/282 drugs (0.7%) with "parosmia," in 6/282 drugs (2.1%) with "dry mouth and anosmia," and in 3/282 drugs (1.0%) with "dry mouth and parosmia." None of these drugs were reported to cause "hyposalivation."

Supplementary online Tables [S2](#odi13199-sup-0001){ref-type="supplementary-material"} and [S3](#odi13199-sup-0001){ref-type="supplementary-material"} present drugs that cause a bitter taste (LLT) or metallic taste (LLT), respectively. Disulfiram (N07BB01), a drug used to treat patients with alcohol abuses, was the only drug reported to cause a garlic taste (LLT).

3.2. Hypogeusia {#odi13199-sec-0010}
---------------

Drug‐induced hypogeusia was reported in 61 drugs (3.7% of 1,645). Hypogeusia was predominantly reported in the drug categories "Antineoplastic and immunomodulating agents" (39.0%) and "Nervous system" (19%). Hypogeusia did not occur in the drug categories "Respiratory system" and "Antiparasitic products, insecticides and repellents" (Table [2](#odi13199-tbl-0002){ref-type="table"}). Table [4](#odi13199-tbl-0004){ref-type="table"} presents all drugs in the IM that are reported to cause hypogeusia. In these 61 drugs, the frequency of hypogeusia was "very common" in 9.5%, "common" in 31.7%, "uncommon" in 25.4%, and "rare or very rare" in 15.9% of the drugs. In 17.5% of the drugs, the "frequency was not known." Hypogeusia coincided in 28/61 drugs (45.9%) with "dry mouth," in 1/61 drugs (1.6%) with "anosmia," and in 2/61 drugs (3.2%) with "dry mouth/anosmia." None of these drugs were reported to cause "hyposalivation."

###### 

Drug‐induced hypogeusia (PT) in all ATC level 1 categories

  ATC level 1                                             ATC level 3                                 Generic name            ATC Code                     LLT MedDRA                   Frequency                                   Specific type of administration         Coinciding adverse effects
  ------------------------------------------------------- ------------------------------------------- ----------------------- ---------------------------- ---------------------------- ------------------------------------------- --------------------------------------- ----------------------------
  ALIMENTARY TRACT AND METABOLISM                         Belladonna and derivatives, plain           Atropine                A03BA01 S01FA01              Hypogeusia                   Frequency not known                         --                                      D
  Intestinal antiinfectives                               Colistin                                    A07AA10 J01XB01         Hypogeusia                   Rare or very rare (\<0.1%)   After inhalation                            --                                      
  ANTIINFECTIVES FOR SYSTEMIC USE                         Antimycotics for systemic use               Micafungin              J02AX05                      Hypogeusia                   Uncommon (0.1%--1%)                         --                                      --
  Direct‐acting antivirals                                Darunavir                                   J05AE10                 Hypogeusia                   Frequency not known          --                                          D                                       
  Drugs for treatment of tuberculosis                     Rifabutin                                   J04AB04                 Hypogeusia                   Rare or very rare (\<0.1%)   --                                          --                                      
  Macrolides, lincosamides, and streptogramins            Claritromycine                              J01FA09                 Hypogeusia                   Rare or very rare (\<0.1%)   --                                          D                                       
  Other antibacterials                                    Methenamine                                 J01XX05                 Hypogeusia                   Rare or very rare (\<0.1%)   --                                          --                                      
  Quinolone antibacterials                                Levofloxacin                                J01MA12                 Hypogeusia                   Rare or very rare (\<0.1%)   After oral and intravenous administration   --                                      
  Ofloxacin                                               J01MA01 S01AE01 S02AA16                     Hypogeusia              Rare or very rare (\<0.1%)   After oral administration    D,A                                                                                 
  ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS              Antimetabolites                             Capecitabine            L01BC06                      Hypogeusia                   Common (1%--10%)                            --                                      D
  Tegafur                                                 L01BC03                                     Hypogeusia              Common (1%--10%)             --                           D                                                                                   
  Hormone antagonists and related agents                  Anastrozole                                 L02BG03                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
  Immunostimulants                                        Aldesleukin                                 L03AC01                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
  Other antineoplastic agents                             Afatinib                                    L01XE13                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
                                                          Axitinib                                    L01XE17                 Hypogeusia                   Very common (\>10%)          --                                          --                                      
                                                          Bosutinib                                   L01XE14                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
                                                          Cabozantinib                                L01XE26                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
                                                          Cisplatin                                   L01XA01                 Hypogeusia                   Frequency not known          --                                          --                                      
                                                          Crizotinib                                  L01XE16                 Hypogeusia                   Very common (\>10%)          --                                          --                                      
                                                          Dasatinib                                   L01XE06                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
                                                          Everolimus                                  L01XE10 L04AA18         Hypogeusia                   Common (1%--10%)             In case of oncologic treatment              D                                       
                                                          Necitumumab                                 L01XC22                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
                                                          Nilotinib                                   L01XE08                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
                                                          Palbociclib                                 L01XE33                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
                                                          Panobinostat                                L01XX42                 Hypogeusia                   Common (1%--10%)             --                                          D                                       
                                                          Sorafenib                                   L01XE05                 Hypogeusia                   Common (1%--10%)             --                                          D                                       
                                                          Temsirolimus                                L01XE09                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
                                                          Trastuzumab                                 L01XC03                 Hypogeusia                   Very common (\>10%)          --                                          D                                       
                                                          Trastuzumab emtansine                       L01XC14                 Hypogeusia                   Common (1%--10%)             --                                          D                                       
                                                          Vandetanib                                  L01XE12                 Hypogeusia                   Common (1%--10%)             --                                          D                                       
                                                          Vismodegib                                  L01XX43                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
  BLOOD AND BLOOD FORMING ORGANS                          Iron, parenteral preparations               Ferric carboxymaltose   B03AC                        Hypogeusia                   Uncommon (0.1%--1%)                         --                                      --
  CARDIOVASCULAR SYSTEM                                   Ace inhibitors, plain                       Captopril               C09AA01                      Hypogeusia                   Common (1%--10%)                            --                                      D
                                                          Enalapril                                   C09AA02                 Hypogeusia                   Frequency not known          --                                          D                                       
                                                          Ramipril                                    C09AA05                 Hypogeusia                   Uncommon (0.1%--1%)          --                                          D,A                                     
  Beta‐blocking agents                                    Esmolol                                     C07AB09                 Hypogeusia                   Uncommon (0.1%--1%)          --                                          D                                       
  Lipid‐modifying agents, plain                           Atorvastatin                                C10AA05                 Hypogeusia                   Uncommon (0.1%--1%)          --                                          --                                      
  DERMATO LOGICALS                                        Antifungals for topical use                 Terbinafine             D01AE15 D01BA02              Hypogeusia                   Uncommon (0.1%--1%)                         --                                      --
  Other dermatological preparations                       Tacrolimus                                  D11AH01 L04AD02 S01XA   Hypogeusia                   Frequency not known          After intravenous administration            --                                      
  GENITOURINARY SYSTEM AND SEX HORMONES                   Hormonal contraceptives for systemic use    Ulipristal              G03AD02 G03XB02              Hypogeusia                   Frequency not known                         When used as emergency anticonceptive   D
  Other urologicals, Incl. antispasmodics                 Solifenacin                                 G04BD08                 Hypogeusia                   Uncommon (0.1%--1%)          --                                          D                                       
                                                          Tiopronine                                  G04BX16                 Hypogeusia                   Uncommon (0.1%--1%)          --                                          --                                      
  MUSCULO SKELETAL SYSTEM                                 Muscle relaxants, centrally acting agents   Baclofen                M03BX01                      Hypogeusia                   Uncommon (0.1%--1%)                         --                                      D
  Specific antirheumatic agents                           Penicillamine                               M01CC01                 Hypogeusia                   Common (1%--10%)             --                                          --                                      
  NERVOUS SYSTEM                                          Anesthetics, local                          Articaine               N01BB08                      Hypogeusia                   Frequency not known                         --                                      --
                                                          Cocaine                                     N01BC01 S01HA01         Hypogeusia                   Frequency not known          --                                          A                                       
                                                          Mepivacaine                                 N01BB03                 Hypogeusia                   Frequency not known          --                                          --                                      
  Antidepressants                                         Duloxetine                                  N06AX21                 Hypogeusia                   Uncommon (0.1%--1%)          --                                          D                                       
                                                          Maprotiline                                 N06AA21                 Hypogeusia                   Frequency not known          --                                          D                                       
  Antiepileptics                                          Pregabalin                                  N03AX16                 Hypogeusia                   Uncommon (0.1%--1%)          --                                          D                                       
  Antimigraine preparations                               Rizatriptan                                 N02CC04                 Hypogeusia                   Uncommon (0.1%--1%)          --                                          D                                       
  Antipsychotics                                          Paliperidone                                N05AX13                 Hypogeusia                   Uncommon (0.1%--1%)          --                                          D                                       
  Dopaminergic agents                                     Opicapone                                   N04BX04                 Hypogeusia                   Uncommon (0.1%--1%)          --                                          D                                       
  Drugs used in addictive disorders                       Varenicline                                 N07BA03                 Hypogeusia                   Frequency not known          --                                          D                                       
  Opioids                                                 Hydromorphone                               N02AA03                 Hypogeusia                   Uncommon (0.1%--1%)          After oral administration                   D                                       
  Psychostimulants, agents used for ADHD and nootropics   Dexamfetamine                               N06BA02                 Hypogeusia                   Rare or very rare (\<0.1%)   --                                          D                                       
  SENSORY ORGANS                                          Antiglaucoma preparations and miotics       Brinzolamide            S01EC04                      Hypogeusia                   Rare or very rare (\<0.1%)                  After systemic administration           D
  SYSTEMIC HORMONAL PREPARATIONS, EXCL.                   Antithyroid preparations                    Carbimazole             H03BB01                      Hypogeusia                   Frequency not known                         --                                      --
                                                          Propylthiouracil                            H03BA02                 Hypogeusia                   Rare or very rare (\<0.1%)   --                                          --                                      
  VARIOUS                                                 Allergens                                   Grass pollen            V01AA02 V01AA                Hypogeusia                   Rare or very rare (\<0.1%)                  After subcutaneous administration       D
  Magnetic resonance imaging contrast media               Gadoteric acid                              V08CA02                 Hypogeusia                   Uncommon (0.1%--1%)          After intravenous administration            --                                      

Abbreviations: A, anosmia, ATC, Anatomic Therapeutical Chemical; D, dry mouth; LLT, lowest level term.
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4. DISCUSSION {#odi13199-sec-0011}
=============

In total, 20% (343/1,645) of the drugs used in the Netherlands has been reported to potentially cause DITD (dysgeusia and hypogeusia). DITD was reported in all ATC level 1 categories, suggesting that all healthcare professionals may frequently encounter the adverse effects of these drugs. Healthcare professionals that treat patients using antineoplastic drugs are most likely to be confronted with DITD. Despite the recorded percentage of our search, the exact incidence of DITD is unclear due to a lack of systematic well controlled clinical trials (Schiffman, [2018](#odi13199-bib-0016){ref-type="ref"}).

To the best of our knowledge, this study is the first comprehensive overview of DITD based on the analysis of a national drug information database which includes adverse effects. The available literature that discusses DITD is fragmented, since previous articles usually report on a specific type of patients with DITD (e.g., cancer) (de Coo & Haan, [2016](#odi13199-bib-0003){ref-type="ref"}; Okada et al., [2016](#odi13199-bib-0014){ref-type="ref"}; Tuccori et al., [2011](#odi13199-bib-0017){ref-type="ref"}), specific drug categories causing DITD (e.g., cardiovascular drugs) (Che, Li, Fang, Reis, & Wang, [2018](#odi13199-bib-0002){ref-type="ref"}; van der Werf, Rovithi, Langius, de van der Schueren, & Verheul, [2017](#odi13199-bib-0018){ref-type="ref"}) or summarize the literature instead of providing an overall analysis of what registered drugs are linked to DITD (Mortazavi, Shafiei, Sadr, & Safiaghdam, [2018](#odi13199-bib-0012){ref-type="ref"}; Schiffman, [2018](#odi13199-bib-0016){ref-type="ref"}; Wang, Glendinning, Grushka, Hummel, & Mansfield, [2017](#odi13199-bib-0019){ref-type="ref"}). In addition, the ATC classification is not always applied, making it difficult to compare the results of the various studies.

Our data source contains predominantly PT level terms. Although this is in accordance with the MedDRA guidelines, it is likely that specific LLT terms like "bitter taste" and "metallic taste" might therefore be underreported compared to previous studies which do not use the MedDRA. It also has to be mentioned that the terms and incidences used in the database (e.g., \"dysgeusia\", \"hypoguesia\") are based on patient‐reported adverse effects during pharmacological developing studies or postmarketing studies. This subjective reporting by patients might lead to a reporting bias or inaccuracy in terminology. The difference between objective and subjective adverse effects measuring is a common point of discussion when reporting on adverse effects and one without a clear solution. When considering taste disorders, there is no commonly used test available for objectifying taste disorders, which makes it impossible to report solely objective data. In order to make future studies on oral adverse effects more comparable, it is recommended that the MedDRA terminology and hierarchy and, if available, objective tests are used during data collection and describing the results. Homogenous reporting of results, on for instance incidences, will lead to clinically more applicable data.

Due to differences in local and regional laws and regulations on drug admission, registered drugs differ per country. Thus, there will be drugs that are reported in the current study that are not available in some countries and reverse. However, with regard to the European countries, most of the reported drugs will be available in all countries. By applying the ATC and MedDRA classification, the data are internationally applicable and could serve as a guidance for future reports on DITD.

The exact mechanisms underlying DITD are still unclear and may vary between individuals. Individual variations may be caused by polypharmacy (drug interactions), dosage differences, and patient‐specific variables (e.g., genetics, age, and medical conditions) (Schiffman, [2018](#odi13199-bib-0016){ref-type="ref"}). Schiffman ([2018](#odi13199-bib-0016){ref-type="ref"}) describes several presumed mechanisms behind DITD. Some drugs have sensory properties that cause a bitter or metallic taste. These drugs interact with the taste buds: (a) after oral application, (b) by diffusion into the saliva after absorption in the gut or intravenous administration, or (c) by accumulation in the taste buds when used chronically. The latter might explain why DITD can occur months or years after the initial usage (e.g., lithium carbonate). Other drugs distort taste and smell signals for sweet or salt, causing a bitter or sour taste perception of food and beverages. The garlic‐like taste caused by disulfiram is due to exhalation of carbon disulfide. Drug--drug interactions can lead to elevated blood plasma levels beyond therapeutic concentrations and therefore cause DITD, which particularly could occur in polypharmacy patients.

Saliva could also play a role in the underlying mechanism of DITD. Saliva protects the external environment of the taste receptor cells and acts as a solvent and transportation medium for taste substances (Matsuo, [2000](#odi13199-bib-0009){ref-type="ref"}). Many drugs are known to cause quantitative or qualitative changes in saliva (Wolff et al., [2017](#odi13199-bib-0022){ref-type="ref"}). Almost 45% of the drugs known to potentially cause DITD coincided with dry mouth as an adverse effect, suggesting that there is at least some correlation. However, the exact correlation is difficult to assess since both MedDRA and the data that underlie the IM do not clearly discriminate between subjective "xerostomia" and objective "hyposalivation." The term "dry mouth" is presumably used for both.

A healthcare professional confronted with a patient with DITD should assess which drug, or drug combination, is presumably responsible for the DITD. This can be done by comparing the temporal onset of DITD with the alterations in the drug usage (e.g., dosage, new drugs). However, as stated before, it is possible that DITD occurs months or years after the initial usage, complicating the assessment of a temporal relationship. Another possibility is to consult pharmaceutical databases and overviews like the approach used in the present study.

Cessation of the drug responsible for DITD will most likely result in a decrease and eventually even recovery of DITD, but this (partial) recovery could take months. If cessation and alterations are not possible, other treatment modalities could be considered to relieve the symptoms. The evidence behind these modalities is scarce and based on research on taste disorders with other causes than DITD. Proposed treatment modalities include improving oral hygiene, suppletion of zinc, stimulation food flavors, saliva substitutes, and administration of alpha lipoic acid (Briggs, [2009](#odi13199-bib-0001){ref-type="ref"}; Femiano, Scully, & Gombos, [2002](#odi13199-bib-0005){ref-type="ref"}; Kumbargere Nagraj et al., [2017](#odi13199-bib-0008){ref-type="ref"}; Schiffman, [2018](#odi13199-bib-0016){ref-type="ref"}).

5. CONCLUSION {#odi13199-sec-0012}
=============

Healthcare professionals are frequently confronted with drugs that are documented with DITD. The exact incidences of DITD remain unclear. This overview supports clinicians in their awareness, diagnosis, and possible treatment of DITD, and could serve as a reference for future research reporting on DITD.
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